Development status of second generation PDE4 inhibitors for asthma and COPD: The story so far

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 57, Issue 1, 2002, Pages 48-64

  Giembycz, Mark A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Airways inflammation; Asthma; Cilomilast; COPD; Cyclic AMP; Phosphodiesterase 4; Roflumilast

Indexed keywords

3 (3 CYCLOPENTYLOXY 4 METHOXYBENZYL) 6 ETHYLAMINO 8 ISOPROPYL 3H PURINE; 4 (3 CHLOROPHENYL) 1,7 DIETHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; ANTACID AGENT; ANTIINFLAMMATORY AGENT; BAY 19 8004; BENZAMIDE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BYK 33043; CICLESONIDE; CILOMILAST; CORTICOSTEROID; DIGOXIN; FLUTICASONE; GLUCOCORTICOID; ISOENZYME; MYLANTA; N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PREDNISOLONE; PUMAFENTRINE; ROFLUMILAST; ROLIPRAM; SALBUTAMOL; SALMETEROL; SB 217263; SB 217493; SB 226461; SB 316708; STEROID; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; AGE; ARTICLE; ASTHMA; BACKACHE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CIRCADIAN RHYTHM; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HUMAN; IC 50; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; INSOMNIA; NAUSEA AND VOMITING; NONHUMAN; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; RHINITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTIGO;

EID: 14244270585     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (117)

1. Effect of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
2. Results of a Phase I trial with SCH55700, a humanised anti-IL-5 antibody, in severe persistent asthma
3. Are eosinophils out of asthma?
4. ERS consensus statement: Optimal assessment and management of chronic pulmonary disease
5. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
6. Descriptive epidemiology of asthma
7. Surveillance for asthma - United States, 1960-1995
8. A national estimate of the economic costs of asthma
9. The costs of asthma
10. The impact of COPD on lung health worldwide: Epidemiology and incidence
11. Mortality by cause for eight regions of the world: Global Burden of Disease Study
12. Evidence-based health-policy lessons from the Global Burden of Disease Study
13. Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease
14. Inhaled corticosteroids are/are not beneficial in chronic obstructive pulmonary disease
15. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant action
16. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents
17. Subtypes of the type 4 cAMP phosphodiesterases: Structure, regulation and selective inhibition
18. Phosphodiesterase (PDE) 4 inhibitors: Drugs of the future?
19. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here?
20. Cyclic AMP-dependent regulation of lipid mediators in white cells: A unifying concept for explaining the efficacy of theophylline in asthma
21. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases
22. Phosphodiesterase 4: Biological underpinnings of the design of improved inhibitors
23. PDE4 inhibitors: The use of molecular cloning in the design and development of novel drugs
24. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity
25. Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a "low affinity" phosphodiesterase 4 conformer
26. 3H]rolipram binding
27. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFa generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer
28. 3H]rolipram binding activity and their relationship to emetic behavior in the ferret
29. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: Correlation between function and interaction with a high-affinity rolipram binding site
30. New drugs in the R & D pipeline: SmithKline-Beecham Seiyaku
31. New drugs in the R & D pipeline - SmithKline-Beecham Seiyaku
32. PDE4 inhibitors 2001: Patent and literature activity 2000
33. SB 207499, a potent and selective phosphodiesterase (PDE) IV inhibitor suppresses activities of several immune and inflammatory cells
34. 1,4-Cyclohexanecarboxylates: Potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma
35. Conformational difference between PDE4 apoenzyme and holoenzyme
36. Molecular basis for an improved therapeutic index of SB 207499, a second generation phosphodiesterase 4 inhibitor
37. Ariflo™ (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic
38. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast
39. Cilomilast: A second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease
40. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro
41. In vivo efficacy in airway disease models of roflumilast, a novel orally-active PDE4 inhibitor
42. The safety and tolerability of Ariflo™ (SB 207499), a novel and selective phosphodiesterase 4 inhibitor, in healthy male volunteers
43. Ariflo™ improves pulmonary function in patients with asthma: Results of a study in patients taking inhaled corticosteroids
44. Safety of Ariflo in a 12-month study of patients with asthma
45. SB 207499 (Ariflo™), a second generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise-induced bronchoconstriction in patients with asthma
46. SB 207499 improves pulmonary function in patients with asthma receiving concomitant inhaled corticosteroids
47. Ariflo efficacy in a 12-month study of patients with asthma
48. Cilomilast
49. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomised, dose-ranging study
50. The efficacy of Ariflo™ (SB 207499), a second generation, oral PDE4 inhibitor, in patients with COPD
51. SB 207499, second generation, oral PDE4 inhibitor, first demonstration of efficacy in patients with COPD
52. The effects of low-dose SB 207499, a second-generation, oral PDE4 inhibitor, in patients with COPD
53. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection
54. Ariflo (SB 207499), a second generation, oral PDE4 inhibitor, improves quality of life in patients with COPD
55. Cilomilast (Ariflo) a potent, selective phosphodiesterase 4 inhibitor, reduces exacerbations in COPD patients: Results of a 6 month trial
56. Cilomilast (Ariflo), a potent, selective inhibitor of phosphodiesterase 4, improves lung function in patients with COPD: Results of a 6 months trial
57. Cilomilast (Ariflo) improves health status in patients with COPD: Results of a 6 month trial
58. Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: Results of a 6-months trial
59. SmithKline-Beecham earnings top expectation
60. + T-lymphocytes and macrophages in patients with chronic obstructive pulmonary disease (COPD): A double blind placebo-controlled, parallel group quantitative study of bronchial biopsies
61. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis
62. Safety and efficacy of the new PDE4 inhibitor roflumilast administered to patients with exercise-induced asthma over 4-weeks
63. Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose
64. Ariflo, a novel and selective oral PDE4 inhibitor, has a favourable metabolic profile with low potential for drug-drug interactions
65. An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally-active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers
66. Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast
67. High oral bioavailability of roflumilast, a new orally-active, once daily PDE4 inhibitor
68. Influence of food intake on the pharmacokinetics of roflumilast, a new, orally-active, selective PDE4 inhibitor
69. The pharmacokinetics of Ariflo (SB 207499), an orally-active novel and selective PDE4 inhibitor, are similar after morning and evening dosing
70. Cilomilast: Pharmacokinetic and pharmacodynamic interactions with digoxin
71. Ariflo (SB 207499), an orally active, second generation selective PDE4 inhibitor, does not interact with a variety of commonly administered COPD medications
72. Warfarin pharmacodynamics unaffected by cilomilast
73. Ariflo, (SB 207499), an orally-active, novel and selective PDE4 inhibitor, has no effect on the steady state pharmacokinetics of digoxin (375 mcg od) in healthy volunteers
74. The pharmacokinetic and tolerability profile of cilomilast (Ariflo), unaffected by co-administration of theophylline
75. Cilomilast (Ariflo) 15 mg bid safety in a six month clinical trial program
76. No interaction of roflumilast, a new, orally-active, selective PDE4 inhibitor, with inhaled salbutamol
77. Roflumilast, a new, orally-active, selective PDE4 inhibitor, does not interact with inhaled budesonide
78. Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by emu gene response in Salmonella typhimurium TA 1535/pSK1002
79. A urinary metabolite ratio that reflects systemic caffeine clearance
80. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine
81. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites
82. Biotransformation of caffeine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1
83. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms
84. Characterization of human liver cytochrome P-450 involved in theophylline metabolism
85. Theophylline metabolism in human liver microsomes: Inhibition studies
86. Metabolism of theophylline by cDNA-expressed human cytochromes P-450
87. Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome P450 in human liver microsomes
88. Characterization of theophylline metabolism in human liver microsomes
89. Characterization of theophylline metabolism by human liver microsomes
90. Effect of smoking on theophylline disposition
91. The influence of cigarette smoking and sex on theophylline disposition
92. Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia
93. Enhanced biotransformation of theophylline in marihuana and tobacco smokers
94. Influence of cigarette smoking on drug metabolism in man
95. Smoking status has no effect on the clearance of a single dose of Ariflo (SB 207499, 15 mg), an orally active, novel, second generation PDE4 inhibitor in healthy male volunteers
96. Smoking has no effect on the pharmacokinetics of roflumilast, a new, orally-active, selective PDE4 inhibitor
97. The safety of cilomilast (Ariflo) co-administration with oral theophylline: Cardiovascular profile
98. The new PDE4 inhibitor roflumilast does not influence cardiovascular function
99. First dose bronchodilating effect of phosphodiesterase-4 (PDE4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients
100. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey
101. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils
102. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4 and PDE4B
103. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D
104. Cyclic AMP phosphodiesterase are localised in regions of the mouse brain associated with reinforcement, movement and affect
105. 3H]rolipram binding autoradiography. Comparison with monkey and rat brain
106. The area postrema and vomiting
107. Emetic reflex arc revealed by expression of the immediate early gene c-fos in the cat
108. Reduction in cis-platin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Anti-emetic trials group
109. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret
110. Palladium-catalyzed cross-coupling reactions for the synthesis of 6,8-disubstituted 1,7-naphthyridines: A novel class of potent and selective phosphodiesterase 4D inhibitors
111. Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid: A potent and selective phosphodiesterase type 4D inhibitor
112. PDE4 inhibitors 1999